BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29129754)

  • 1. CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer.
    Agrawal S; Dwivedi M; Ahmad H; Chadchan SB; Arya A; Sikandar R; Kaushik S; Mitra K; Jha RK; Dwivedi AK
    Nanomedicine; 2018 Feb; 14(2):327-337. PubMed ID: 29129754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondria Targeting and Destabilizing Hyaluronic Acid Derivative-Based Nanoparticles for the Delivery of Lapatinib to Triple-Negative Breast Cancer.
    Lee SY; Cho HJ
    Biomacromolecules; 2019 Feb; 20(2):835-845. PubMed ID: 30566834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
    Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
    Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
    Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
    Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversing P-Glycoprotein-Associated Multidrug Resistance of Breast Cancer by Targeted Acid-Cleavable Polysaccharide Nanoparticles with Lapatinib Sensitization.
    Sui J; He M; Yang Y; Ma M; Guo Z; Zhao M; Liang J; Sun Y; Fan Y; Zhang X
    ACS Appl Mater Interfaces; 2020 Nov; 12(46):51198-51211. PubMed ID: 33147005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronic acid-engineered Bcl-2 inhibitor nanocrystals for site-specific delivery to breast tumor cells.
    Panwar D; Thakor P; Sharma M; Bakshi AK; Bhavana V; Srivastava V; Mishra PR; Singh SB; Mehra NK
    Nanomedicine (Lond); 2023 Jun; 18(15):1005-1023. PubMed ID: 37530043
    [No Abstract]   [Full Text] [Related]  

  • 7. Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain.
    Wan X; Zheng X; Pang X; Pang Z; Zhao J; Zhang Z; Jiang T; Xu W; Zhang Q; Jiang X
    Oncotarget; 2016 Jun; 7(23):34038-51. PubMed ID: 27086917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44 targeted redox-triggered self-assembly with magnetic enhanced EPR effects for effective amplification of gambogic acid to treat triple-negative breast cancer.
    Sang M; Han L; Luo R; Qu W; Zheng F; Zhang K; Liu F; Xue J; Liu W; Feng F
    Biomater Sci; 2019 Dec; 8(1):212-223. PubMed ID: 31674634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.
    Werfel TA; Wang S; Jackson MA; Kavanaugh TE; Joly MM; Lee LH; Hicks DJ; Sanchez V; Ericsson PG; Kilchrist KV; Dimobi SC; Sarett SM; Brantley-Sieders DM; Cook RS; Duvall CL
    Cancer Res; 2018 Apr; 78(7):1845-1858. PubMed ID: 29358172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronic Acid-Coated Camptothecin Nanocrystals for Targeted Drug Delivery to Enhance Anticancer Efficacy.
    Wang J; Muhammad N; Li T; Wang H; Liu Y; Liu B; Zhan H
    Mol Pharm; 2020 Jul; 17(7):2411-2425. PubMed ID: 32437163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyaluronic acid-coated pH sensitive poly (β-amino ester) nanoparticles for co-delivery of embelin and TRAIL plasmid for triple negative breast cancer treatment.
    Xu Y; Liu D; Hu J; Ding P; Chen M
    Int J Pharm; 2020 Jan; 573():118637. PubMed ID: 31550511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo.
    Jian YS; Chen CW; Lin CA; Yu HP; Lin HY; Liao MY; Wu SH; Lin YF; Lai PS
    Int J Nanomedicine; 2017; 12():2315-2333. PubMed ID: 28392690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
    Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
    Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation.
    Huo ZJ; Wang SJ; Wang ZQ; Zuo WS; Liu P; Pang B; Liu K
    Cancer Sci; 2015 Oct; 106(10):1429-37. PubMed ID: 26177628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating metastatic triple negative breast cancer with CD44/neuropilin dual molecular targets of multifunctional nanoparticles.
    Liang DS; Zhang WJ; Wang AT; Su HT; Zhong HJ; Qi XR
    Biomaterials; 2017 Aug; 137():23-36. PubMed ID: 28528300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo.
    Zhong Y; Goltsche K; Cheng L; Xie F; Meng F; Deng C; Zhong Z; Haag R
    Biomaterials; 2016 Apr; 84():250-261. PubMed ID: 26851390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A CD44-targeted Cu(ii) delivery 2D nanoplatform for sensitized disulfiram chemotherapy to triple-negative breast cancer.
    Gao Z; Li Y; Zhang Y; An P; Chen F; Chen J; You C; Wang Z; Sun B
    Nanoscale; 2020 Apr; 12(15):8139-8146. PubMed ID: 32236229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
    Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy.
    Wang S; Cao M; Deng X; Xiao X; Yin Z; Hu Q; Zhou Z; Zhang F; Zhang R; Wu Y; Sheng W; Zeng Y
    Adv Healthc Mater; 2015 Jan; 4(2):281-90. PubMed ID: 25044638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced anti-tumor and anti-metastasis therapy for triple negative breast cancer by CD44 receptor-targeted hybrid self-delivery micelles.
    Yang Y; Long Y; Wang Y; Ren K; Li M; Zhang Z; Xiang B; He Q
    Int J Pharm; 2020 Mar; 577():119085. PubMed ID: 32001290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.